Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
The gut microbiota has an important role in the pathogenesis of hepatic encephalopathy(HE). Rifaximin, an intestinal non-absorbable antibacterial agent, is effective in the treatment of HE. However, whether long-term prophylactic use induces antibacterial resistance and its mechanism for treating HE...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2022-01-01
|
| Sarja: | Frontiers in Cellular and Infection Microbiology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fcimb.2021.761192/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|